Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure
Open Access
- 1 April 2009
- journal article
- Published by Elsevier in Kidney International
- Vol. 75 (8) , 800-808
- https://doi.org/10.1038/ki.2008.690
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Partial nephrectomy as a model for uremic cardiomyopathy in the mouseAmerican Journal of Physiology-Renal Physiology, 2008
- Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarctionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Identification of S664 TSC2 Phosphorylation as a Marker for Extracellular Signal-Regulated Kinase–Mediated mTOR Activation in Tuberous Sclerosis and Human CancerCancer Research, 2007
- Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic CardiomyopathyHypertension, 2006
- Effects of Short Daily versus Conventional Hemodialysis on Left Ventricular Hypertrophy and Inflammatory MarkersJournal of the American Society of Nephrology, 2005
- Role of p38? MAPK in cardiac apoptosis and remodeling after myocardial infarctionJournal of Molecular and Cellular Cardiology, 2005
- Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in MiceCirculation, 2003
- RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overloadJournal of Clinical Investigation, 1999
- Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobinAmerican Journal of Kidney Diseases, 1999
- Impact of left ventricular hypertrophy on survival in end-stage renal diseaseKidney International, 1989